Collectively, the co-introduced CCR2-CCL2 axis potentiated not only tumor trafficking activity, but also WT1 epitope-responsiveness mediated by these double-transfected CTLs, resulting in enhanced anti-lung cancer functionality in vivo, notably in the phase immediately after therapeutic infusion. This evidence concerns the gene CCL2 and neoplasm.